The forecast for spending on pharmaceutical benefits in 2025-26, which is just 8 weeks from finalisation, is $5.6 billion higher than it was four years ago, assuming most of that growth will be offset by rebates. This is not to defend the status quo but to encourage accuracy. …
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Funding for new chemotherapy-free immunotherapy combination for follicular lymphoma
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News -
First new brain cancer treatment listed on PBS after more than 20 years
August 3, 2026 - - Latest News -
Listing offers treatment option for Australians with tumour induced osteomalacia
August 3, 2026 - - Latest News -
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News